Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Annu Rev Biochem ; 89: 667-693, 2020 06 20.
Artículo en Inglés | MEDLINE | ID: mdl-32169021

RESUMEN

Myosins are among the most fascinating enzymes in biology. As extremely allosteric chemomechanical molecular machines, myosins are involved in myriad pivotal cellular functions and are frequently sites of mutations leading to disease phenotypes. Human ß-cardiac myosin has proved to be an excellent target for small-molecule therapeutics for heart muscle diseases, and, as we describe here, other myosin family members are likely to be potentially unique targets for treating other diseases as well. The first part of this review focuses on how myosins convert the chemical energy of ATP hydrolysis into mechanical movement, followed by a description of existing therapeutic approaches to target human ß-cardiac myosin. The next section focuses on the possibility of targeting nonmuscle members of the human myosin family for several diseases. We end the review by describing the roles of myosin in parasites and the therapeutic potential of targeting them to block parasitic invasion of their hosts.


Asunto(s)
Inhibidores Enzimáticos/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológico , Miosinas/metabolismo , Neoplasias/tratamiento farmacológico , Enfermedades del Sistema Nervioso/tratamiento farmacológico , Infecciones por Protozoos/tratamiento farmacológico , Adenosina Trifosfato/química , Adenosina Trifosfato/metabolismo , Regulación Alostérica/efectos de los fármacos , Animales , Fenómenos Biomecánicos , Cryptosporidium/efectos de los fármacos , Cryptosporidium/enzimología , Inhibidores Enzimáticos/química , Expresión Génica , Insuficiencia Cardíaca/enzimología , Insuficiencia Cardíaca/genética , Insuficiencia Cardíaca/patología , Humanos , Familia de Multigenes , Mutación , Miosinas/antagonistas & inhibidores , Miosinas/clasificación , Miosinas/genética , Neoplasias/enzimología , Neoplasias/genética , Neoplasias/patología , Enfermedades del Sistema Nervioso/enzimología , Enfermedades del Sistema Nervioso/genética , Enfermedades del Sistema Nervioso/patología , Plasmodium/efectos de los fármacos , Plasmodium/enzimología , Infecciones por Protozoos/enzimología , Infecciones por Protozoos/genética , Infecciones por Protozoos/patología , Toxoplasma/efectos de los fármacos , Toxoplasma/enzimología
2.
PLoS Pathog ; 16(7): e1008599, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32692767

RESUMEN

Heme oxygenase (HO-1) mediates the enzymatic cleavage of heme, a molecule with proinflammatory and prooxidant properties. HO-1 activity deeply impacts host capacity to tolerate infection through reduction of tissue damage or affecting resistance, the ability of the host to control pathogen loads. In this Review, we will discuss the contribution of HO-1 in different and complex protozoan infections, such as malaria, leishmaniasis, Chagas disease, and toxoplasmosis. The complexity of these infections and the pleiotropic effects of HO-1 constitute an interesting area of study and an opportunity for drug development.


Asunto(s)
Hemo-Oxigenasa 1/metabolismo , Infecciones por Protozoos/enzimología , Animales , Humanos , Tolerancia Inmunológica/fisiología
3.
Curr Top Microbiol Immunol ; 420: 155-174, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30105424

RESUMEN

Parasites exist within most ecological niches, often transitioning through biologically and chemically complex host environments over the course of their parasitic life cycles. While the development of technologies for genetic engineering has revolutionised the field of functional genomics, parasites have historically been less amenable to such modification. In light of this, parasitologists have often been at the forefront of adopting new small-molecule technologies, repurposing drugs into biological tools and probes. Over the last decade, activity-based protein profiling (ABPP) has evolved into a powerful and versatile chemical proteomic platform for characterising the function of enzymes. Central to ABPP is the use of activity-based probes (ABPs), which covalently modify the active sites of enzyme classes ranging from serine hydrolases to glycosidases. The application of ABPP to cellular systems has contributed vastly to our knowledge on the fundamental biology of a diverse range of organisms and has facilitated the identification of potential drug targets in many pathogens. In this chapter, we provide a comprehensive review on the different forms of ABPP that have been successfully applied to parasite systems, and highlight key biological insights that have been enabled through their application.


Asunto(s)
Parásitos/metabolismo , Proteoma/análisis , Proteoma/metabolismo , Proteómica/métodos , Infecciones por Protozoos/metabolismo , Infecciones por Protozoos/parasitología , Animales , Dominio Catalítico , Humanos , Parásitos/enzimología , Proteoma/química , Infecciones por Protozoos/enzimología
4.
Molecules ; 23(7)2018 Jul 17.
Artículo en Inglés | MEDLINE | ID: mdl-30018257

RESUMEN

Sterol 14α-demethylase (SDM) is essential for sterol biosynthesis and is the primary molecular target for clinical and agricultural antifungals. SDM has been demonstrated to be a valid drug target for antiprotozoal therapies, and much research has been focused on using SDM inhibitors to treat neglected tropical diseases such as human African trypanosomiasis (HAT), Chagas disease, and leishmaniasis. Sterol C24-methyltransferase (24-SMT) introduces the C24-methyl group of ergosterol and is an enzyme found in pathogenic fungi and protozoa but is absent from animals. This difference in sterol metabolism has the potential to be exploited in the development of selective drugs that specifically target 24-SMT of invasive fungi or protozoa without adversely affecting the human or animal host. The synthesis and biological activity of SDM and 24-SMT inhibitors are reviewed herein.


Asunto(s)
Inhibidores de 14 alfa Desmetilasa , Proteínas Fúngicas , Metiltransferasas , Micosis , Infecciones por Protozoos , Proteínas Protozoarias , Esterol 14-Desmetilasa , Inhibidores de 14 alfa Desmetilasa/síntesis química , Inhibidores de 14 alfa Desmetilasa/química , Inhibidores de 14 alfa Desmetilasa/uso terapéutico , Animales , Proteínas Fúngicas/antagonistas & inhibidores , Proteínas Fúngicas/química , Proteínas Fúngicas/metabolismo , Humanos , Metiltransferasas/antagonistas & inhibidores , Metiltransferasas/química , Metiltransferasas/metabolismo , Micosis/tratamiento farmacológico , Micosis/enzimología , Infecciones por Protozoos/tratamiento farmacológico , Infecciones por Protozoos/enzimología , Proteínas Protozoarias/antagonistas & inhibidores , Proteínas Protozoarias/química , Proteínas Protozoarias/metabolismo , Esterol 14-Desmetilasa/química , Esterol 14-Desmetilasa/metabolismo
5.
Biochim Biophys Acta ; 1814(11): 1567-76, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21884827

RESUMEN

The chemical properties of the B(6) vitamers are uniquely suited for wide use as cofactors in essential reactions, such as decarboxylations and transaminations. This review addresses current efforts to explore vitamin B(6) dependent enzymatic reactions as drug targets. Several current targets are described that are found amongst these enzymes. The focus is set on diseases caused by protozoan parasites. Comparison across a range of these organisms allows insight into the distribution of potential targets, many of which may be of interest in the development of broad range anti-protozoan drugs. This article is part of a Special Issue entitled: Pyridoxal Phosphate Enzymology.


Asunto(s)
Enzimas/metabolismo , Infecciones por Protozoos/tratamiento farmacológico , Fosfato de Piridoxal/metabolismo , Animales , Aspartato Aminotransferasas/efectos de los fármacos , Aspartato Aminotransferasas/metabolismo , Liasas de Carbono-Azufre/efectos de los fármacos , Liasas de Carbono-Azufre/metabolismo , Cisteína Sintasa/efectos de los fármacos , Cisteína Sintasa/metabolismo , Glicina Hidroximetiltransferasa/efectos de los fármacos , Glicina Hidroximetiltransferasa/metabolismo , Humanos , Hidrolasas/efectos de los fármacos , Hidrolasas/metabolismo , Ornitina Descarboxilasa/efectos de los fármacos , Ornitina Descarboxilasa/metabolismo , Infecciones por Protozoos/enzimología , Infecciones por Protozoos/metabolismo , Trypanosoma cruzi/enzimología
7.
RNA Biol ; 9(6): 751-71, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22699555

RESUMEN

RNA helicases unwind their RNA substrates in an ATP-dependent reaction, and are central to all cellular processes involving RNA. They have important roles in viral life cycles, where RNA helicases are either virus-encoded or recruited from the host. Vertebrate RNA helicases sense viral infections, and trigger the innate antiviral immune response. RNA helicases have been implicated in protozoic, bacterial and fungal infections. They are also linked to neurological disorders, cancer, and aging processes.   Genome-wide studies continue to identify helicase genes that change their expression patterns after infection or disease outbreak, but the mechanism of RNA helicase action has been defined for only a few diseases. RNA helicases are prognostic and diagnostic markers and suitable drug targets, predominantly for antiviral and anti-cancer therapies. This review summarizes the current knowledge on RNA helicases in infection and disease, and their growing potential as drug targets.


Asunto(s)
ARN Helicasas/fisiología , Virosis/enzimología , Animales , Infecciones Bacterianas/enzimología , Interacciones Huésped-Patógeno , Humanos , Inmunidad Innata , Modelos Moleculares , Micosis/enzimología , Neoplasias/enzimología , Enfermedades del Sistema Nervioso/enzimología , Estructura Terciaria de Proteína , Infecciones por Protozoos/enzimología , ARN/metabolismo , Virosis/inmunología , Virosis/virología
8.
J Biochem Mol Toxicol ; 24(4): 270-7, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20135636

RESUMEN

With the increasing evidence of protease involvement in several diseases, novel strategies for drug development involve the use of protease inhibitors (PIs). The local balance between protease inhibitors and proteases is an important determinant of the occurrence and progression of a particular disease. Hence, enzymes and their cognate inhibitors are finding their applications as diagnostic and prognostic markers. PIs are widely implicated for their use in host defense against infection, tissue repair and matrix production, blood coagulation, cancer, and they are, therefore, the current focus as therapeutic alternatives for major diseases such as AIDS and Alzheimer's diseases. This review is a brief summary of the varied role of protein protease inhibitors in controlling the activity of aberrant enzymes in several diseases afflicting mankind today.


Asunto(s)
Inhibidores de Proteasas/uso terapéutico , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida/enzimología , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/enzimología , Animales , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/enzimología , Asma/tratamiento farmacológico , Asma/enzimología , Enfermedades Cardiovasculares/tratamiento farmacológico , Enfermedades Cardiovasculares/enzimología , Enfisema/tratamiento farmacológico , Enfisema/enzimología , Helmintiasis/tratamiento farmacológico , Helmintiasis/enzimología , Humanos , Infecciones/tratamiento farmacológico , Infecciones/enzimología , Micosis/tratamiento farmacológico , Micosis/enzimología , Neoplasias/tratamiento farmacológico , Neoplasias/enzimología , Osteoporosis/tratamiento farmacológico , Osteoporosis/enzimología , Infecciones por Protozoos/tratamiento farmacológico , Infecciones por Protozoos/enzimología , Mordeduras de Serpientes/tratamiento farmacológico , Mordeduras de Serpientes/enzimología
9.
Immunopharmacol Immunotoxicol ; 31(2): 159-73, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18785049

RESUMEN

Caspases are cysteine aspartases acting either as initiators (caspases 8, 9, and 10) or executioners (caspases 3, 6, and 7) to induce programmed cell death by apoptosis. Parasite infections by certain intracellular protozoans increase host cell life span by targeting caspase activation. Conversely, caspase activation, followed by apoptosis of lymphocytes and other cells, prevents effective immune responses to chronic parasite infection. Here we discuss how pharmacological inhibition of caspases might affect the immunity to protozoan infections, by either blocking or delaying apoptosis.


Asunto(s)
Antiprotozoarios/uso terapéutico , Apoptosis/efectos de los fármacos , Inhibidores de Caspasas , Infecciones por Protozoos/tratamiento farmacológico , Animales , Antiprotozoarios/inmunología , Apoptosis/inmunología , Humanos , Tolerancia Inmunológica/efectos de los fármacos , Ratones , Infecciones por Protozoos/enzimología , Infecciones por Protozoos/inmunología , Receptores de Muerte Celular/inmunología
10.
Subcell Biochem ; 44: 219-29, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-18084896

RESUMEN

Cellular redox metabolism is considered to be involved in the pathophysiology of diseases caused by protozoal parasites such as Toxoplasma, Trypanosoma, Leishmania, and Plasmodia. Redox reactions furthermore are thought to play a major role in the action of and the resistance to some clinically used antiparasitic drugs. Interestingly, in malarial parasites, the antioxidant enzymes catalase and glutathione peroxidase are absent which indicates a crucial role of the thioredoxin system in redox control. Besides a glutathione peroxidase-like thioredoxin peroxidase and a glutathione S-transferase with slight peroxidase activity, Plasmodium falciparum (the causative agent of tropical malaria) possesses four classical peroxiredoxins: Two peroxiredoxins of the typical 2-Cys Prx class, one 1-Cys peroxiredoxin with homology to the atypical 2-Cys Prx class, and a peroxiredoxin of the 1-Cys Prx class have been identified and partially characterized In our article we give an introduction to redox-based drug development strategies against protozoal parasites and summarize the present knowledge on peroxiredoxin systems in Plasmodium.


Asunto(s)
Eucariontes/enzimología , Glutatión Transferasa/metabolismo , Peroxirredoxinas/metabolismo , Infecciones por Protozoos/enzimología , Proteínas Protozoarias/farmacología , Animales , Catalasa , Diseño de Fármacos , Eucariontes/patogenicidad , Glutatión Peroxidasa , Glutatión Transferasa/antagonistas & inhibidores , Humanos , Peroxirredoxinas/antagonistas & inhibidores , Infecciones por Protozoos/tratamiento farmacológico , Proteínas Protozoarias/antagonistas & inhibidores , Homología de Secuencia de Aminoácido , Tiorredoxinas
11.
J Leukoc Biol ; 104(4): 729-735, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-30020539

RESUMEN

Guanylate-binding proteins (GBPs) are conserved family of IFN-inducible GTPases that play an important role in the host immunity against bacterial, viral, and protozoan pathogens. GBPs protect the host by associating with intracellular microbes, their vacuolar niche or, in the case of viruses, with their replication complex. This association results in a restriction of the respective pathogen, yet the exact molecular mechanisms of the antimicrobial functions of GBPs are still unclear. Recent work has linked the GBPs with the activation of inflammasomes, multi-protein complexes that assemble upon recognition of pathogen- or host-derived signals and that drive the release of cytokines and host cell death. Here, we will focus on the most recent findings that have started to unravel the manifold restriction mechanism controlled by GBPs in mouse and human cells, and that shed light on the molecular cues that control GBP recruitment to bacterial membranes.


Asunto(s)
Proteínas de Unión al GTP/fisiología , Inmunidad Innata , Infecciones/inmunología , Animales , Infecciones Bacterianas/enzimología , Infecciones Bacterianas/inmunología , Caspasas/fisiología , Membrana Celular/metabolismo , Citocinas/metabolismo , Humanos , Infecciones/enzimología , Inflamasomas/inmunología , Lipopolisacáridos/metabolismo , Mamíferos/inmunología , Ratones , Enfermedades Parasitarias/enzimología , Enfermedades Parasitarias/inmunología , Transporte de Proteínas , Infecciones por Protozoos/enzimología , Infecciones por Protozoos/inmunología , Virosis/enzimología , Virosis/inmunología
12.
Fundam Clin Pharmacol ; 31(1): 37-53, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27487199

RESUMEN

CYP51 is an enzyme of sterol biosynthesis pathway present in animals, plants, protozoa and fungi. This enzyme is described as an important drug target that is still of interest. Therefore, in this work, we reviewed the structure and function of CYP51 and explored the molecular modeling approaches for the development of new antifungal and antiprotozoans that target this enzyme. Crystallographic structures of CYP51 of some organisms have already been described in the literature, which enable the construction of homology models of other organisms' enzymes and molecular docking studies of new ligands. The binding mode and interactions of some new series of azoles with antifungal or antiprotozoan activities has been studied and showed important residues of the active site. Molecular modeling is an important tool to be explored for the discovery and optimization of CYP51 inhibitors with better activities, pharmacokinetics, and toxicological profiles.


Asunto(s)
Inhibidores de 14 alfa Desmetilasa/farmacología , Antifúngicos/farmacología , Antiprotozoarios/farmacología , Diseño de Fármacos , Simulación del Acoplamiento Molecular , Esterol 14-Desmetilasa/metabolismo , Inhibidores de 14 alfa Desmetilasa/química , Inhibidores de 14 alfa Desmetilasa/toxicidad , Animales , Antifúngicos/química , Antifúngicos/toxicidad , Antiprotozoarios/química , Antiprotozoarios/toxicidad , Sitios de Unión , Humanos , Micosis/tratamiento farmacológico , Micosis/enzimología , Micosis/microbiología , Unión Proteica , Estructura Secundaria de Proteína , Infecciones por Protozoos/tratamiento farmacológico , Infecciones por Protozoos/enzimología , Infecciones por Protozoos/parasitología , Esterol 14-Desmetilasa/biosíntesis , Especificidad por Sustrato
13.
Drug Discov Today ; 10(2): 121-8, 2005 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-15718161

RESUMEN

Parasitic apicomplexans are responsible for some of the most severe worldwide health problems, including malaria, toxoplasmosis and cryptosporidiosis. These parasites are characterized by a bifunctional enzyme, dihydrofolate reductase-thymidylate synthase (DHFR-TS), which has a crucial role in pyrimidine biosynthesis. Inhibitors of DHFR have been successful in the treatment of toxoplasmosis and malaria. However, there is currently no effective therapy for cryptosporidiosis, and despite early successes against malaria, resistance to DHFR inhibitors in malaria parasites has now become a global problem. Novel DHFR inhibitors, designed using the recently revealed crystal structures of the enzymes from two parasitic protozoa, are in development.


Asunto(s)
Antiprotozoarios/farmacología , Eucariontes/efectos de los fármacos , Antagonistas del Ácido Fólico/farmacología , Infecciones por Protozoos/tratamiento farmacológico , Tetrahidrofolato Deshidrogenasa/metabolismo , Animales , Antiprotozoarios/uso terapéutico , Ensayos Clínicos como Asunto , Eucariontes/enzimología , Eucariontes/fisiología , Antagonistas del Ácido Fólico/uso terapéutico , Humanos , Infecciones por Protozoos/enzimología , Tetrahidrofolato Deshidrogenasa/química
14.
Trends Parasitol ; 21(2): 58-63, 2005 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-15664527

RESUMEN

Opportunistic parasitic infections are an important cause of morbidity and mortality in people infected with HIV. Since the introduction of highly active antiretroviral therapy (HAART), there has been a marked reduction in the occurrence and clinical course of these parasitic infections. Although these changes have been attributed to the restoration of cell-mediated immunity induced by either non-nucleoside reverse transcriptase inhibitors or HIV protease inhibitors, in combination with at least two nucleoside reverse transcriptase inhibitors included in HAART, there is evidence that HIV protease inhibitors have a direct inhibitory effect on the proteases of parasites. The results of studies on opportunistic parasitic infections conducted both before and during the HAART era indicate the need to develop clinical trials on the efficacy of HIV protease inhibitors in controlling parasitic infections in individuals with HIV or other immunocompromised individuals and laboratory investigations on aspartyl proteases of parasites as an important target for the development of new drugs.


Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Infecciones Oportunistas Relacionadas con el SIDA/parasitología , Eucariontes/enzimología , Infecciones por VIH/parasitología , Inhibidores de la Proteasa del VIH/farmacología , VIH/enzimología , Infecciones por Protozoos/virología , Infecciones Oportunistas Relacionadas con el SIDA/inmunología , Animales , Terapia Antirretroviral Altamente Activa , Ácido Aspártico Endopeptidasas/metabolismo , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inmunología , Inhibidores de la Proteasa del VIH/uso terapéutico , Humanos , Infecciones por Protozoos/tratamiento farmacológico , Infecciones por Protozoos/enzimología , Infecciones por Protozoos/inmunología
15.
Expert Opin Ther Targets ; 19(12): 1689-704, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26235676

RESUMEN

INTRODUCTION: The carbonic anhydrases (CAs, EC 4.2.1.1), a group of ubiquitously expressed metalloenzymes, are involved in numerous physiological and pathological processes, as well as in the growth and virulence of pathogens belonging to bacteria, fungi and protozoa. AREAS COVERED: CAs belonging to at least four genetic families, the α-, ß-, γ- and η-CAs, were discovered and characterized in many pathogens: i) Bacteria encode enzymes from one or more such families, which were investigated as potential drug targets. Inhibition of bacterial CAs by sulfonamides/phenol derivatives lead to inhibition of growth of the pathogen for Helicobacter pylori, Mycobacterium tuberculosis, Brucella suis; ii) Fungi encode for α- and ß-CAs, and inhibitors of the sulfonamide, thiol or dithiocarbamate type inhibited the growth of some of them (Malassezia globosa, Candida albicans, Crytpococcus neoformans, etc) in vivo; and iii) Protozoa encode α-, ß- or η-CAs. Sulfonamide, thiols and hydroxamates effectively killed such parasites (Trypanosoma cruzi, Leishmania donovani chagasi, Plasmodium falciparum) in vivo. EXPERT OPINION: None of the microorganism CAs is validated as drug targets as yet, but the inhibitors designed against many such enzymes showed interesting in vitro/in vivo results. By interfering with the activity of CAs from microorganisms, both pH homeostasis as well as crucial biosynthetic reactions are impaired, which lead to significant antiinfective effects, not yet exploited for obtaining pharmacological agents. As resistance to the clinically used antiinfectives is a serious healthcare problem worldwide, inhibition of parasite CAs may constitute an alternative approach for obtaining such agents with novel mechanisms of action.


Asunto(s)
Inhibidores de Anhidrasa Carbónica/farmacología , Anhidrasas Carbónicas/efectos de los fármacos , Terapia Molecular Dirigida , Animales , Antibacterianos/farmacología , Antifúngicos/farmacología , Antiprotozoarios/farmacología , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/enzimología , Infecciones Bacterianas/microbiología , Anhidrasas Carbónicas/metabolismo , Diseño de Fármacos , Humanos , Micosis/tratamiento farmacológico , Micosis/enzimología , Micosis/microbiología , Infecciones por Protozoos/tratamiento farmacológico , Infecciones por Protozoos/enzimología , Infecciones por Protozoos/microbiología
16.
Trends Parasitol ; 19(4): 182-7, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12689649

RESUMEN

Parasitic protozoa contain an abundance of cysteine peptidases that are crucial for a range of important biological processes. The most studied cysteine peptidases of parasitic protozoa belong to the group of papain-like enzymes known as clan CA. However, several more recently identified cysteine peptidases differ fundamentally from the clan CA enzymes and have been included together in clan CD. Enzymes of this clan have now been identified in parasitic protozoa. Many have important roles and also differ significantly from known mammalian counterparts. The main characteristics of clan CD enzymes are outlined here, in particular glycosylphosphatidylinositol (GPI):protein transamidase, metacaspase and separase, and their differences from the clan CA enzymes are described.


Asunto(s)
Cisteína Endopeptidasas/química , Cisteína Endopeptidasas/clasificación , Endopeptidasas , Eucariontes/enzimología , Infecciones por Protozoos/enzimología , Secuencia de Aminoácidos , Aminoaciltransferasas/metabolismo , Animales , Caspasas/metabolismo , Proteínas de Ciclo Celular/metabolismo , Cisteína Endopeptidasas/metabolismo , Eucariontes/clasificación , Glicosilfosfatidilinositoles/metabolismo , Modelos Moleculares , Datos de Secuencia Molecular , Separasa
17.
Int J Parasitol ; 26(5): 533-42, 1996 May.
Artículo en Inglés | MEDLINE | ID: mdl-8818734

RESUMEN

Newly hatched female Muscovy ducklings were randomly separated into 2 groups of 12 and 1 group of 13. Ducklings in the first 2 groups were each orally inoculated with 0.5 ml of sterile normal saline containing 0 and 3 x 10(6) trophozoites of Cochlosoma anatis, respectively. Birds in the third group were each orally inoculated with 3 x 10(6) trophozoites for 5 consecutive days. Birds were weighed daily for the first 5 days and then on days 7, 14 and 21 post-inoculation (p.i.). On days 6, 7, 8, 13, 14, 15, 20, 21 and 22 p.i., 1 bird from each group was killed and samples of intestine at 7 levels were taken for trophozoite counts, mucosal disaccharidase analyses and morphometric analysis. Body weights did not differ among treatment groups at any time during the experiment. Trophozoite numbers did not change over the period 6-22 days p.i. Trophozoite numbers were lowest in the anterior small intestine and increased distally, but very few were observed in the caecum. Crypt depth was greater in all regions of the small intestine in inoculated groups compared to uninoculated controls, and was significantly increased in the duodenum, proximal jejunum and mid-jejunum (P < 0.05). Villus height was greater in inoculated groups compared to controls at all levels of the intestine and was significantly increased in the duodenum, proximal jejunum and ileum (P < 0.05). Mucosal palatinase and maltase activity in the small intestine were reduced in inoculated groups compared to uninoculated controls; palatinase activities were significantly reduced in the proximal and mid-jejunum and maltase activities were significantly reduced in the mid-jejunum (P < 0.05). Sucrase activities were significantly increased at all levels of the small intestine in inoculated ducklings compared to uninoculated controls (P < 0.05). Although no clinical signs were evident, Cochlosoma infection significantly altered intestinal morphometrics and mucosal enzyme concentrations in ducklings, in several cases in a counter-intuitive direction.


Asunto(s)
Enfermedades de las Aves/patología , Patos , Eucariontes/patogenicidad , Infecciones Protozoarias en Animales , Animales , Animales Recién Nacidos , Enfermedades de las Aves/enzimología , Enfermedades de las Aves/parasitología , Disacaridasas/metabolismo , Eucariontes/aislamiento & purificación , Femenino , Mucosa Intestinal/patología , Infecciones por Protozoos/enzimología , Infecciones por Protozoos/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA